DEF: Axsome Therapeutics Sets Date for 2025 Annual Stockholders Meeting, Outlines Key Proposals

Axsome Therapeutics announces its 2025 Annual Meeting of Stockholders to be held virtually on June 6, 2025, featuring proposals including director election, incentive plan approval, auditor ratification, and executive compensation advisory vote.

Summary

• Axsome Therapeutics will hold its 2025 Annual Meeting of Stockholders virtually on June 6, 2025, at 9:00 a.m. local time.
• Stockholders of record as of April 14, 2025, are entitled to vote.
• The meeting will address the election of a Class I director, approval of the 2025 Long-Term Incentive Plan, ratification of Deloitte & Touche LLP as the independent auditor, and an advisory vote on executive compensation.
• The Board of Directors recommends voting for all proposals.
• The company had 49,219,312 shares of common stock outstanding as of the record date.
• The 2025 Long-Term Incentive Plan seeks stockholder approval to grant equity awards to key individuals.
• As of March 31, 2025, 2,501,504 shares remained available for issuance under the 2015 Plan and 9,830,908 shares were subject to outstanding awards under our 2015 Plan, in each case calculated based on the target number of shares subject to outstanding performance-based awards.

Sentiment

Score: 7

Explanation: The document is neutral in tone, providing necessary information for stockholders to make informed decisions. The outlook is cautiously optimistic, focusing on incentivizing employees and aligning interests.

Positives

• The Board is actively seeking stockholder input on key decisions.
• The proposed 2025 Long-Term Incentive Plan aims to align employee and shareholder interests.
• The company is committed to good corporate governance practices, including independent board committees and a code of ethics.
• The company's equity burn rate has decreased from 7% in 2022 to 4% in 2024.

Negatives

• Approval of the 2025 Long-Term Incentive Plan will dilute existing shareholders.
• The company's overhang was 19% in 2024.

Risks

• Failure to approve the 2025 Long-Term Incentive Plan could hinder the company's ability to attract and retain key talent.
• The classification of the Board of Directors into three classes with staggered three-year terms may have the effect of delaying or preventing changes in our control or management.

Future Outlook

The Compensation Committee believes that the shares available for issuance under the 2025 Plan should result in an adequate number of shares of Common Stock for future awards for approximately three years.

Management Comments

• Very truly yours, /s/ HERRIOT TABUTEAU, M.D. Herriot Tabuteau, M.D. Chief Executive Officer, President, and Chairman of the Board

Industry Context

The document references peer group companies for executive compensation benchmarking, indicating an awareness of industry standards and competitive practices.

Comparison to Industry Standards

• The Compensation Committee uses a peer group of 16 publicly-held U.S. pharmaceutical and biotechnology companies with comparable operations based on factors like development programs, employee count, therapeutic area, and market capitalization.
• Peer companies include ACADIA Pharmaceuticals, Insmed Incorporated, Alector, Inc., Intra-Cellular Therapies, Inc., Allogene Therapeutics, Inc., Karuna Therapeutics, Inc., Amicus Therapeutics, Inc., Revance Therapeutics, Inc., Catalyst Pharmaceuticals, Inc., Sage Therapeutics, Inc., Corcept Therapeutics Incorporated, Supernus Pharmaceuticals, Inc., Denali Therapeutics Inc., Ultragenyx Pharmaceutical, Inc., Harmony Biosciences Holdings, Inc., and Vanda Pharmaceuticals Inc.
• Axsome ranked at the 70th percentile of current market cap and at the 35th percentile of trailing four quarters revenue of the above-reference peer group of companies as of August 2023.

Stakeholder Impact

• Approval of the proposals will impact shareholders through potential dilution and alignment of management incentives.
• Employees will be affected by the 2025 Long-Term Incentive Plan, which aims to attract, retain, and motivate key personnel.

Next Steps

• Stockholders are encouraged to vote on the proposals before the June 6, 2025 deadline.
• The company will announce preliminary voting results at the Annual Meeting and publish final results in a Current Report on Form 8-K.

Key Dates

Keywords

Annual Meeting, Proxy Statement, Stockholders, Incentive Plan, Board of Directors, Executive Compensation, Deloitte & Touche, Director Election, Corporate Governance, Equity Awards, Axsome Therapeutics